Phospho-ATRIP(S239) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q8WXE1 |
---|---|
Other Accession | Q9N077, NP_115542.2 |
Gene ID | 84126 |
---|---|
Other Names | ATR-interacting protein, ATM and Rad3-related-interacting protein, ATRIP, AGS1 |
Target/Specificity | The synthetic peptide sequence is selected from aa 234-248 of HUMAN ATRIP |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | ATRIP |
---|---|
Synonyms | AGS1 |
Function | Required for checkpoint signaling after DNA damage. Required for ATR expression, possibly by stabilizing the protein. |
Cellular Location | Nucleus. Note=Redistributes to discrete nuclear foci upon DNA damage |
Tissue Location | Ubiquitous.. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The product of this gene is an essential component of the DNA damage checkpoint, and binds to single-stranded DNA coated with replication protein A that accumulates at sites of DNA damage. The encoded protein interacts with the ataxia telangiectasia and Rad3 related protein, a checkpoint kinase, resulting in accumulation of the kinase at intranuclear foci induced by DNA damage. Multiple transcript variants encoding different isoforms have been found for this gene.
References
Bailey, S.D., et al. Diabetes Care (2010) In press :
Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)
Vega, A., et al. Gynecol. Oncol. 112(1):210-214(2009)
Myers, J.S., et al. Cancer Res. 67(14):6685-6690(2007)
Venere, M., et al. Cancer Res. 67(13):6100-6105(2007)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.